{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-011545","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.581181+00:00","generated_at":"2026-05-15T09:41:52.009457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M","bullets":["Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.","Full-year 2025 revenue $41.7M, up 12% YoY; net loss narrowed to $10.5M from $17.7M.","Gross margin improved to 82.4% in Q4 (from 58.0%) due to new earnout structure after asset purchase from Biofrontera AG.","Adjusted EBITDA was $4.9M in Q4 vs. -$1.4M; full-year Adjusted EBITDA -$10.6M vs. -$15.3M.","Pipeline: PDUFA date for sBCC September 2026; positive Phase 3 AK results; Phase 2b acne data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-011545","json":"https://secwatch.observer/filing/0001493152-26-011545.json","markdown":"https://secwatch.observer/filing/0001493152-26-011545.md","text":"https://secwatch.observer/filing/0001493152-26-011545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/0001493152-26-011545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:41:52.009457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}